Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
Alejandra Maciel, Ali Cullors, Andrew A Lukowiak, Jorge Garces AltheaDx, San Diego, CA, USA Abstract: The burden of depression significantly impacts the patient, the health care system, and society, at large. Medication management guided by pharmacogenetics has been shown to increase therapeutic e...
Guardado en:
Autores principales: | Maciel A, Cullors A, Lukowiak AA, Garces J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4d941f45cf7e49d995b22e26b72b4f95 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacogenetics of Antidepressants: from Genetic Findings to Predictive Strategies
por: L. K. Khokhlov, et al.
Publicado: (2019) -
Efecto de las variantes de VKORC1 y CYP2C9 sobre la dosis de anticoagulantes orales en individuos chilenos
por: Benavides,Felipe, et al.
Publicado: (2015) -
Pharmacogenetics
Publicado: (1991) -
PHARMACOECONOMICS OF APPLICATION OF HEPATOPROTECTORS IN THERAPY OF DRUG-INDUCED LIVER INJURY AFTER CHEMOTHERAPY
por: D. D. Morikov, et al.
Publicado: (2017) -
Pharmacogenetics of hypoglycemic agents
por: Irina Vladimirovna Kononenko, et al.
Publicado: (2015)